MedPath

KRABEVA Bevacizumab (r-DNA Origin) Concentrate for Solution for Intravenous Infusion 25mg/mL

Registration Number: MAL20126007AZ

Approved
Approval ID

373dced4c2307925

Registration Number

MAL20126007AZ

Registration Date

Jul 7, 2025

Regulatory Authority
NPRA
Malaysia

Product Information

Additional product specifications and packaging information as registered with NPRA Malaysia.

Product Specifications

PRODUCT SPECIFICATIONS

Official SourceNPRA Database
Available Package Types1 type
Last UpdatedJul 7, 2025

PACKAGING INFORMATION (1)

1 VialsAvailable
Package Size: 1 Vials
Status: NPRA Approved

Active Ingredients

Active pharmaceutical ingredients contained in this NPRA-approved product.

Ingredients (1)

BevacizumabActive
Monograph: 贝伐珠单抗

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

KRABEVA Bevacizumab (r-DNA Origin) Concentrate for Solution for Intravenous Infusion 25mg/mL - NPRA Drug Approval Details | MedPath - Medical Intelligence Platform